Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates
ZacksNektar (NKTR) delivered earnings and revenue surprises of -19.05% and 36.26%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?